大腸癌新藥介紹：Braftovi®

大腸癌是全球第三大被診斷為男女性別的癌症，男性發病率僅次於肺癌和乳腺癌，是僅次於肺癌、肝癌和胃癌的第四大癌症死亡原因。使用5-fluorouracil（5-FU）、irinotecan和oxaliplatin三種組合，合併bevacizumab當作第一線治療BRAF突變的轉移性（metastatic colorectal cancer, mCRC）病人而預後不好時，美國食品藥品監督管理局（FDA）核准第二代BRAF抑制劑Braftovi®（encorafenib）合併使用Erbitux®（cetuximab）於治療具有BRAF V600E突變的轉移性結直腸癌（mCRC）的成人病人。最常見的副作用為疲勞、貧血、肌酸磷酸激酶升高、AST升高和尿路感染。藥物動力學方面：Braftovi®的最高血漿濃度的時間（Tmax）為2小時且至少86%的劑量被吸收，半衰期（t1/2）為3.5小時。

關鍵字

大腸癌； BRAF抑制劑；轉移性疾病

並列摘要

Colorectal cancer is the third most common cancer in the world. The incidence rate of men is second only to lung cancer and breast cancer, and is the fourth leading cause of cancer death after lung cancer, liver cancer and gastric cancer. When using the three combinations of 5-fluorouracil (5-FU), irinotecan and oxaliplatin, combined with bevacizumab as the first-line treatment of BRAF mutation metastatic colorectal cancer (mCRC) patients, the prognosis is not good. The U.S. Food and Drug Administration ( FDA) approved the second-generation BRAF inhibitor Braftovi®(encorafenib) combined with Erbitux®(cetuximab) for the treatment of adult patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The most common side effects are fatigue, anemia, increased creatine phosphokinase, increased AST, and urinary tract infections. Pharmacokinetics: The time (Tmax) of the highest plasma concentration of Braftov® is 2 hours and at least 86% of the dose is absorbed and the half-life (t1/2) is 3.5 hours.

並列關鍵字

colorectal cancer ； BRAF inhibitors ； metastatic disease

參考文獻

Choong, M. K., & Tsafnat, G. (2012). Genetic and epigenetic biomarkers of colorectal cancer. Clinical Gastroenterology and Hepatology, 10(1), 9-15.

Google Scholar

衛生福利部國民健康署（2020，11月2日）．大腸癌防治概況．取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=615&pid=1126

Google Scholar

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ... Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359-E386.

Google Scholar

Sánchez-Gundín, J., Fernández-Carballido, A. M., Martínez-Valdivieso, L., Barreda-Hernández, D., & Torres-Suárez, A. I. (2018). New trends in the therapeutic approach to metastatic colorectal cancer. International journal of Medical Sciences, 15(7), 659-665.